- Home
- BNAI vs MIRA Comparison
BNAI vs MIRA Comparison
Compare BNAI & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNAI
- MIRA
- Stock Information
- Founded
- BNAI 2018
- MIRA 2020
- Country
- BNAI United States
- MIRA United States
- Employees
- BNAI N/A
- MIRA N/A
- Industry
- BNAI
- MIRA Biotechnology: Pharmaceutical Preparations
- Sector
- BNAI
- MIRA Health Care
- Exchange
- BNAI NYSE
- MIRA Nasdaq
- Market Cap
- BNAI 20.7M
- MIRA 19.5M
- IPO Year
- BNAI N/A
- MIRA 2023
- Fundamental
- Price
- BNAI $0.34
- MIRA $1.66
- Analyst Decision
- BNAI Strong Buy
- MIRA Strong Buy
- Analyst Count
- BNAI 1
- MIRA 2
- Target Price
- BNAI $6.00
- MIRA $14.00
- AVG Volume (30 Days)
- BNAI 824.9K
- MIRA 3.1M
- Earning Date
- BNAI 08-13-2025
- MIRA 08-12-2025
- Dividend Yield
- BNAI N/A
- MIRA N/A
- EPS Growth
- BNAI N/A
- MIRA N/A
- EPS
- BNAI N/A
- MIRA N/A
- Revenue
- BNAI $60,000.00
- MIRA N/A
- Revenue This Year
- BNAI N/A
- MIRA N/A
- Revenue Next Year
- BNAI N/A
- MIRA N/A
- P/E Ratio
- BNAI N/A
- MIRA N/A
- Revenue Growth
- BNAI N/A
- MIRA N/A
- 52 Week Low
- BNAI $0.23
- MIRA $0.62
- 52 Week High
- BNAI $3.74
- MIRA $5.01
- Technical
- Relative Strength Index (RSI)
- BNAI 45.68
- MIRA 73.89
- Support Level
- BNAI $0.34
- MIRA $1.07
- Resistance Level
- BNAI $0.39
- MIRA $1.39
- Average True Range (ATR)
- BNAI 0.04
- MIRA 0.14
- MACD
- BNAI -0.00
- MIRA 0.04
- Stochastic Oscillator
- BNAI 28.52
- MIRA 90.77
About BNAI BRAND ENGAGEMENT NETWORK INC
Brand Engagement Network Inc is a generative AI (GenAI) company specializing in conversational AI solutions. Through its secure, human-like AI agents, available in different modalities, the company seeks to transform consumer engagement and elevate customer experience, productivity, and business performance.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.